Symbols

TVTX

Travere Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 1

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

High Cash/net Profit Ratio

EPS Beats Expectation

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About TVTX

Travere Therapeutics, Inc.

A company that developing therapies to treat rare disorders like nephrology, hepatology, and metabolism

Industry

Pharmaceutical

Established Date

02/08/2008

Listing Date

01/10/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

497

Fiscal Year Ends

12-31

Website

travere.com

Security Type

Common stock

Office address

3611 Valley Centre Drive, Suite 300, San Diego, CA 92130

Business

Introduction

Travere Therapeutics, Inc., was incorporated in Oklahoma on February 8, 2008 and re-incorporated in Delaware in February 2011. Travere is an integrated biopharmaceutical company headquartered in San Diego, California, dedicated to developing and delivering life-changing therapies for patients with rare renal and metabolic diseases. The Company regularly evaluates and takes actions as appropriate to expand its product line and approved products through product licensing and acquisitions to meet the unmet medical needs of patients with rare diseases and tap areas that the Company believes have good growth potential.

Company Financials

EPS

TVTX has released its 2025 Q4 earnings. EPS was reported at 0.37, versus the expected -0.04, beating expectations. The chart below visualizes how TVTX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

TVTX has released its 2025 Q4 earnings report, with revenue of 129.69M, reflecting a YoY change of 73.41%, and net profit of 2.73M, showing a YoY change of 104.53%. The Sankey diagram below clearly presents TVTX's revenue sources and cost distribution.